Avadhut D Joshi
Overview
Explore the profile of Avadhut D Joshi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
684
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gallia G, Holdhoff M, Brem H, Joshi A, Hann C, Bai R, et al.
Neurooncol Adv
. 2021 Jan;
3(1):vdaa154.
PMID: 33506200
Background: Mebendazole is an anthelmintic drug introduced for human use in 1971 that extends survival in preclinical models of glioblastoma and other brain cancers. Methods: A single-center dose-escalation and safety...
2.
Joshi A, Botham R, Schlein L, Roth H, Mangraviti A, Borodovsky A, et al.
Oncotarget
. 2017 Nov;
8(46):80124-80138.
PMID: 29113289
Purpose: Glioblastoma is a deadly brain cancer with a median survival time of ∼15 months. Ionizing radiation plus the DNA alkylator temozolomide (TMZ) is the current standard therapy. PAC-1, a...
3.
Mittal A, Chaturvedi N, Rohlfsen R, Gupta P, Joshi A, Hegde G, et al.
PLoS One
. 2013 Aug;
8(8):e70352.
PMID: 23936412
Earlier, we reported that CTLA4 expression is inversely correlated with CD38 expression in chronic lymphocytic leukemia (CLL) cells. However, the specific role of CTLA4 in CLL pathogenesis remains unknown. Therefore,...
4.
Joshi A, Loilome W, Siu I, Tyler B, Gallia G, Riggins G
PLoS One
. 2012 Oct;
7(10):e44372.
PMID: 23056179
Glioblastoma multiforme (GBM) is the most common intracranial cancer but despite recent advances in therapy the overall survival remains about 20 months. Whole genome exon sequencing studies implicate mutations in...
5.
Joshi A, Parsons D, Velculescu V, Riggins G
Mol Cancer
. 2011 Feb;
10:17.
PMID: 21314958
Background: Glioblastoma Multiforme (GBM) is the most common and invasive astrocytic tumor associated with dismal prognosis. Treatment for GBM patients has advanced, but the median survival remains a meager 15...
6.
Seltzer M, Bennett B, Joshi A, Gao P, Thomas A, Ferraris D, et al.
Cancer Res
. 2010 Nov;
70(22):8981-7.
PMID: 21045145
Mutation at the R132 residue of isocitrate dehydrogenase 1 (IDH1), frequently found in gliomas and acute myelogenous leukemia, creates a neoenzyme that produces 2-hydroxyglutarate (2-HG) from α-ketoglutarate (α-KG). We sought...
7.
Clark E, Joshi D, Grimm A, Joshi A, Wang P, Joshi S
Int J Oncol
. 2010 Jul;
37(3):645-53.
PMID: 20664933
Umbilical cord blood cells (UCBC) are a rich source of immature immune effector and accessory cells, including dendritic cells. UCBC-derived cytotoxic T lymphocytes (CTLs) generated against human breast cancer or...
8.
Rao S, Edwards J, Joshi A, Siu I, Riggins G
J Neurooncol
. 2009 Jul;
96(2):169-79.
PMID: 19609742
Glioblastoma Multiforme (GBM) is a malignant brain cancer that develops after accumulating genomic DNA damage that often includes gene amplifications and/or deletions. These copy number changes can be a critical...
9.
Loilome W, Joshi A, ap Rhys C, Piccirillo S, Vescovi A, Angelo V, et al.
J Neurooncol
. 2009 Apr;
94(3):359-66.
PMID: 19340397
The Fibroblast Growth Factor (FGF) signaling pathway is reported to stimulate glioblastoma (GBM) growth. In this work we evaluated the effect of FGF2, FGF receptor (FGFR), and small molecule inhibition...
10.
Hegde G, Peterson K, Emanuel K, Mittal A, Joshi A, Dickinson J, et al.
Mol Cancer Res
. 2008 Dec;
6(12):1928-36.
PMID: 19074837
B-cell chronic lymphocytic leukemia (B-CLL) is characterized by an accumulation of neoplastic B cells due to their resistance to apoptosis and increased survival. Among various factors, the tumor microenvironment is...